The addition of Kynamro helps to reduce low-density lipoprotein-cholesterol (LDL-C), apolipoprotein B, total cholesterol, and non-high density lipoprotein-cholesterol (non HDL-C).
FORBES: FDA Approves Mipomersen For Homozygous Familial Hypercholesterolemia
KYNAMRO, given as a 200 mg weekly subcutaneous injection, has been approved as an adjunct to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (Apo B), total cholesterol (TC), and non-high density lipoprotein-cholesterol (non HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).
FORBES: FDA Approves Mipomersen For Homozygous Familial Hypercholesterolemia
Low-density lipoprotein (LDL) or bad cholesterol levels should be below 100, and high-density lipoprotein (HDL) should measure 35 or above.
Torcetrapib aims to raise good cholesterol, or high-density lipoprotein, by blocking the cholesterol ester transfer protein.
High-density lipoprotein, better known as HDL or "good cholesterol, " has become a medical mainstay.
ETC-216 is a slightly different version of a protein in high-density lipoprotein, the so-called good cholesterol.
For a few years it thought it had one: good cholesterol, also known as high-density lipoprotein.
Alcohol, including beer, in moderation raises high-density lipoprotein or HDL, known as good cholesterol, says Dr. R.
High-density lipoprotein is thought to carry the cholesterol from the artery wall to the liver for disposal.
Nothing on the market today increases "good cholesterol, " or high-density lipoprotein (HDL), as much as torcetrapib did in early clinical trials.
In 19 patients with low levels of HDL (high-density lipoprotein), the Pfizer combo raised HDL counts by 61%, with few side effects.
The drug is designed to boost high-density lipoprotein (HDL), nicknamed "good cholesterol" because it appears to actually clear plaque from the arteries and reduce the risk of heart attack.
Researchers speculating about what went wrong thought perhaps torcetrapib made HDL that didn't work, or that HDL itself (short for high-density lipoprotein, and often called "good cholesterol") was less powerful than they thought.
For the company's finances, the most important new drug is torcetrapib, a new medicine designed to raise high-density lipoprotein (HDL), the "good cholesterol, " which is thought to help clear plaque from the arteries.
But other companies are filing in behind, including Merck, Roche , Novartis and Kos Pharmaceuticals, the small firm whose niacin preparations are the only marketed drugs to raise 'good cholesterol, ' also known as high-density lipoprotein (HDL).
It also lowered the so-called good cholesterol, or high-density lipoprotein (HDL), and it did not enter the cell, a characteristic Medford wanted hisdrug to have, because some of the oxidation process takes place within cellular membranes.
In the study where it helped patients lose weight, the drug also raised good cholesterol, or high-density lipoprotein (HDL), by 23%, almost as much as Niaspan, the sustained-release niacin drug made by Kos Pharmaceuticals (nasdaq: KOSP - news - people ) that is the main currently available treatment for raising HDL. Rimonabont also cut triglycerides, another risk factor for heart disease, by 16%.
But other companies are filing in behind, including Merck (nyse: MRK - news - people ), Roche , Novartis (nyse: NVS - news - people ) and Kos Pharmaceuticals (nasdaq: KOSP - news - people ), the small firm whose niacin preparations are the only marketed drugs to raise 'good cholesterol, ' also known as high-density lipoprotein (HDL).
In Ridker's study, patients with high bad cholesterol, or low-density lipoprotein and high CRP had heart attacks, strokes or heart procedures 9.9% of the time compared with 4.9% of the time for patients where both risks were low.
The most common type of cholesterol problem is a high LDL (low density lipoprotein) which is usually best treated with a statin, of which there are at least four on the market.
Big studies have shown that low HDL levels may be as important as high levels of low-density lipoprotein (LDL) in causing heart attacks.
Up until now, evidence for statins has been mainly in people with high "bad" cholesterol, properly known as low-density lipoprotein (LDL).
应用推荐